Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blueprint prices IPO above range, raises $147m

This article was originally published in Scrip

Executive Summary

Blueprint Medicines has priced its heavily oversubscribed initial public offering (IPO) of just over 8 million shares at $18.00 per share, above the initial range of $15-$17. This led to gross proceeds of $147m and a market capitalization of $465m, "a pleasing result for a young biotechnology company not in the immune-oncology space and with two drugs about to enter the clinic," noted Thilo Schroeder, partner at Blueprint investor Nextech Invest and former member of its board.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC028588

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel